Lymphoma News

Eyal Gottlieb, PhD, has been named vice president for research at The University of Texas MD Anderson Cancer Center.

For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.

Women who underwent implant reconstruction after mastectomy for breast cancer or ductal carcinoma in situ had a significantly increased relative risk for anaplastic large cell lymphoma, according to findings published in JAMA Network Open.

Scientists from Denmark and the United States have engineered a yeast commonly used in foods to produce the precursor molecules for the anticancer agent vinblastine, a drug that has been in shortage several times in recent years.

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.

More than 2 years after the COVID-19 pandemic began, new treatments, vaccines and preventive measures have improved safety and disease outcomes for patients with cancer, according to a speaker at Chemotherapy Foundation Symposium.

Matthew Matasar, MD, MS, has been named chief of blood disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.

Early referral to transplantation can increase access to transplant and cell therapies, as well as improve outcomes among patients with hematologic malignancies, according to a speaker at Chemotherapy Foundation Symposium.

The FDA approved brentuximab vedotin in combination with chemotherapy for treatment of certain children with Hodgkin lymphoma, according to the agent’s manufacturer.

The treatment landscape for relapsed or refractory indolent non-Hodgkin lymphoma continues to shift from chemoimmunotherapy to targeted treatments, according to a speaker at Chemotherapy Foundation Symposium.